BACKGROUND:Quadrivalent human papillomavirus (HPV) vaccine, for protection against sexually transmitted HPV infection, is licensed for females and males 9-26 years on a 3-dose schedule (0, 2, and 6 months; Standard schedule). Vaccine uptake has been low and catch-up vaccination of older adolescents using an alternate dosing schedule may increase coverage. This study tested the non-inferiority of the immunogenicity of an alternate dosing schedule (0, 2, 12 months) among college age males. METHODS:220 18-25 year old males were randomly assigned to Standard or Alternate schedules. Blood samples were drawn immediately before Dose 1 and 2-6 weeks after Dose 3 and analyzed for antibody titers using a Luminex immunoassay. A value <1.5 for the upper 95% confidence interval (CI) bound of the Standard to Alternate schedule geometric mean titer (GMT) ratio was deemed non-inferior. RESULTS: Participants averaged 21.3 years old; 19.1% were non-white; completion rate was 93%. The anti-HPV titers for the Alternate schedule group were non-inferior to those of Standard schedule group for all four HPV vaccine virus types. Our results also demonstrated superiority of the Alternate schedule group for all four HPV vaccine virus types. CONCLUSION: A delayed third dose at 12 months is immunologically non-inferior and superior for four HPV virus types. Using an alternate dosing schedule offers more flexibility to receive the 3-dose HPV vaccine and may result in higher vaccination rates among college-age males.
RCT Entities:
BACKGROUND: Quadrivalent human papillomavirus (HPV) vaccine, for protection against sexually transmitted HPV infection, is licensed for females and males 9-26 years on a 3-dose schedule (0, 2, and 6 months; Standard schedule). Vaccine uptake has been low and catch-up vaccination of older adolescents using an alternate dosing schedule may increase coverage. This study tested the non-inferiority of the immunogenicity of an alternate dosing schedule (0, 2, 12 months) among college age males. METHODS: 220 18-25 year old males were randomly assigned to Standard or Alternate schedules. Blood samples were drawn immediately before Dose 1 and 2-6 weeks after Dose 3 and analyzed for antibody titers using a Luminex immunoassay. A value <1.5 for the upper 95% confidence interval (CI) bound of the Standard to Alternate schedule geometric mean titer (GMT) ratio was deemed non-inferior. RESULTS:Participants averaged 21.3 years old; 19.1% were non-white; completion rate was 93%. The anti-HPV titers for the Alternate schedule group were non-inferior to those of Standard schedule group for all four HPV vaccine virus types. Our results also demonstrated superiority of the Alternate schedule group for all four HPV vaccine virus types. CONCLUSION: A delayed third dose at 12 months is immunologically non-inferior and superior for four HPV virus types. Using an alternate dosing schedule offers more flexibility to receive the 3-dose HPV vaccine and may result in higher vaccination rates among college-age males.
Authors: Richard J Hillman; Anna R Giuliano; Joel M Palefsky; Stephen Goldstone; Edson D Moreira; Eftyhia Vardas; Carlos Aranda; Heiko Jessen; Daron G Ferris; Francois Coutlee; J Brooke Marshall; Scott Vuocolo; Richard M Haupt; Dalya Guris; Elizabeth I O Garner Journal: Clin Vaccine Immunol Date: 2011-12-07
Authors: Sharon J M Kessels; Helen S Marshall; Maureen Watson; Annette J Braunack-Mayer; Rob Reuzel; Rebecca L Tooher Journal: Vaccine Date: 2012-04-03 Impact factor: 3.641
Authors: Richard K Zimmerman; Chyongchiou Jeng Lin; Jonathan M Raviotta; Mary Patricia Nowalk Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452
Authors: Jonathan M Raviotta; Mary Patricia Nowalk; Chyongchiou Jeng Lin; Hsin-Hui Huang; Richard K Zimmerman Journal: Am J Mens Health Date: 2014-11-11
Authors: Hanna Bergman; Brian S Buckley; Gemma Villanueva; Jennifer Petkovic; Chantelle Garritty; Vittoria Lutje; Alina Ximena Riveros-Balta; Nicola Low; Nicholas Henschke Journal: Cochrane Database Syst Rev Date: 2019-11-22
Authors: Timo Vesikari; Lars Østergaard; Javier Diez-Domingo; Jacek Wysocki; Carl-Erik Flodmark; Johannes Beeslaar; Joseph Eiden; Qin Jiang; Kathrin U Jansen; Thomas R Jones; Shannon L Harris; Robert E O'Neill; Laura J York; Graham Crowther; John L Perez Journal: J Pediatric Infect Dis Soc Date: 2015-08-04 Impact factor: 3.164
Authors: Allison M Brady; Emmanuel B Walter; Lauri E Markowitz; Elizabeth R Unger; Gitika Panicker Journal: Hum Vaccin Immunother Date: 2020-01-22 Impact factor: 3.452